|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||||||||||||
  Bipolar DisordersVolume 7 Issue 4, Pages 382 - 387 Published Online: 15 Jul 2005 Journal compilation © 2010 John Wiley & Sons A/S The Official Journal of The International Society for Bipolar Disorders
Abstract | References | Full Text: HTML, PDF (Size: 137K) | Related Articles | Citation Tracking  Brief Report Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect The authors of this paper do not have any commercial associations that might pose a conflict of interest in connection with this manuscript. Copyright 2005 Blackwell Munksgaard KEYWORDS bipolar • lithium • meta-analysis • systematic review Deshauer D, Fergusson D, Duffy A, Albuquerque J, Grof P. Re-evaluation of randomized control trials of lithium monotherapy: a cohort effect.
Bipolar Disord 2005: 7: 382–387. © Blackwell Munksgaard, 2005 ABSTRACTObjective: The reported reduction of lithium's efficacy in the prophylaxis of bipolar illness has been attributed to various factors, including diagnostic changes and heterogeneous study designs. We attempted to quantify the impact of pre-randomization enrichment designs and diagnostic drift on randomized controlled trials (RCTs) of lithium maintenance therapy. Methods: Using the Cochrane RCT search filter, MEDLINE, EMBASE, and PSYCHINFO were searched (1966 to June 2004) for all available randomized studies using the text word 'lithium'. Studies of 1 year minimum duration in bipolar disorder involving lithium and placebo arms were identified. Superiority trials without a placebo arm, discontinuation and mirror image studies were excluded. Standardized scales were used to assess randomization and allocation concealment. Results: Nine RCTs enrolling 1432 bipolar I and II patients, randomizing 341 to lithium and 386 to placebo were identified, with 705 reported pre-randomization dropouts. The pooled odds of remaining recurrence free in two non-enriched RCTS using Research Diagnostic Criteria (RDC) or Feighner criteria were 3.2:1 (95% CI 0.65–15.46) trending in favor of lithium over placebo, and 22.0:1 (95% CI 7.0–68.7) for three trials using lithium enrichment and excluding atypical bipolar disorder. The odds of remaining recurrence free using DSM-IV criteria and lamotrigine enrichment were 1.9:1 (95% CI 1.2–2.8). Conclusion: Lithium maintenance RCTs differ in patient selection, design, and outcome. A cohort effect can be associated with the use of pre-randomization enrichment phases and, to a lesser extent, with diagnostic drift, compromising straightforward comparisons across three decades of lithium monotherapy in bipolar illness. Received 6 July 2004, revised and accepted for publication 18 February 2005 | 
|
|
| ||||||||||||||||
|
|
|||||||||||||||||||
 | Personality and Mental Health |
| |
